The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises at least one 5′-triphosphate and/or at least one 5′-diphosphate. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection, and/or ameliorating, minimizing, reversing, and/or preventing persistent SARS-CoV-2 viral infection, and/or minimizing or preventing SARS-CoV-2 viral infection-derived mortality and/or lethality, in a subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in a tumor-bearing subject. In certain embodiments, compounds and/or compositions of the disclosure are useful for treating, ameliorating, and/or preventing SARS-CoV-2 viral infection in an immune-compromised and/or immunodeficient subject.

A wireless wideband transceiver may be able to communicate with multiple frequency-hopped spread-spectrum (FHSS) devices concurrently over multiple frequencies over a short range by including a plurality of digital chains corresponding to the FHSS physical channels, individually and dynamically compensated for in-phase/quadrature imbalance in the transmit and/or receive portion. To further improve communications the transceiver may also mitigate cross interference between adjacent channel signals that are received and/or transmitted simultaneously, avoid false reception and/or transmission of co-channel signals, delay respective FHSS channels transmissions relative to other channels transmissions, speed up connection to FHSS devices and coordinate Time Division Duplexing (TDD) operation according to application dependent TX/RX binary pattern. A device that includes such a transceiver (FHSS-hotspot) may enable the concurrent usage of multiple commercially available FHSS peripheral devices without the need for additional personal host devices to be carried along with them, and in addition enable the concurrent usage of multiple commercially available FHSS personal data devices while reducing their radiation and/or latency and/or usage cost and/or power, to establish a localized multi-device multimedia session, and/or to interface with a communications network to communicate with remote parties, and/or to interface with broadcast devices to stream contents.

A wireless wideband transceiver may be able to communicate with multiple frequency-hopped spread-spectrum (FHSS) devices concurrently over multiple frequencies over a short range by including a plurality of digital chains corresponding to the FHSS physical channels, individually and dynamically compensated for in-phase/quadrature imbalance in the transmit and/or receive portion. To further improve communications the transceiver may also mitigate cross interference between adjacent channel signals that are received and/or transmitted simultaneously, avoid false reception and/or transmission of co-channel signals, delay respective FHSS channels transmissions relative to other channels transmissions, speed up connection to FHSS devices and coordinate Time Division Duplexing (TDD) operation according to application dependent TX/RX binary pattern. A device that includes such a transceiver (FHSS-hotspot) may enable the concurrent usage of multiple commercially available FHSS peripheral devices without the need for additional personal host devices to be carried along with them, and in addition enable the concurrent usage of multiple commercially available FHSS personal data devices while reducing their radiation and/or latency and/or usage cost and/or power, to establish a localized multi-device multimedia session, and/or to interface with a communications network to communicate with remote parties, and/or to interface with broadcast devices to stream contents.

The present disclosure relates to immunogenic compositions comprising tetanus, diphtheria, and acellular pertussis (Tdap) antigens, and a toll-like receptor 9 (TLR9) agonist, such as oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions may further comprise an aluminum salt adjuvant to which the Tdap antigens are adsorbed. The immunogenic compositions are suitable for active booster immunization against tetanus, diphtheria, and pertussis in an individual in need thereof.

The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.

The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.

The present invention includes methods for detecting cancer in a subject and measuring the effectiveness of a cancer treatment. In certain embodiments, the invention includes assessing the level of unshielded RN7SL1 RNA in a sample from a subject.

The present invention includes methods for detecting cancer in a subject and measuring the effectiveness of a cancer treatment. In certain embodiments, the invention includes assessing the level of unshielded RN7SL1 RNA in a sample from a subject.

Disclosed herein are cells including pluripotent stem cells that conditionally express an immunosuppressive factor and related methods of their use and generation. In some embodiments, the cells disclosed do not express MHC I and MHC II human leukocyte antigens, and in some cases, also do not express one or more TCR complexes. In some embodiments, hypoimmunogenicity of the cells is controlled by activation of a controllable expression system upon contacting the cells with a specific factor or agent.